X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Earnings data Q1 2023

Earnings data Q2 2023

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q4 2022 Earnings Conference Call March 21, 2023 9:00 AM ET Company Participants Dan Ferry - LifeSci Advisors, IR Paula Ragan - CEO Adam Mostafa - CFO Murray Stewart - Interim Chief Medical Officer Mark Baldry - Chief Commercial Officer Conference Call Participants Divya Rao - TD Cowen Edward Tenthoff - Piper Sandler Kristen Kluska - Cantor Fitzgerald Swayampakula Ramakanth - H.C. Wainwright Operator Thank you for standing by.

X4 Pharmaceuticals, Inc. (XFOR) Q4 2022 Earnings Call Transcript

Upcoming expected milestones for investigational therapy mavorixafor in WHIM syndrome include: presentation of additional Phase 3 clinical data in 2Q 2023, NDA submission in early

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the fourth quarter and twelve months ended December 31, 2022 on March 21, 2023.

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023

BOSTON, March 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today announced that, effective on February 28, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 54,900 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4's compensation committee of the board of directors.

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock

Akebia Therapeutics

Astra Space

SoFi Technologies

Volitionrx Limited

Exicure Inc

Insiders are buying these penny stocks but are they worth the risk? The post Penny Stocks To Buy: 6 Insider Picks Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: 6 Insider Picks Before 2023

Oral presentation further details positive data from mavorixafor Phase 1b clinical trial in people with chronic idiopathic, cyclic, or congenital neutropenia

X4 Pharmaceuticals' Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced today the pricing of its previously announced underwritten public offering of 52,300,000 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 6,800,000 shares of its common stock, and accompanying Class C warrants to purchase 29,550,000 shares of its common stock at an exercise price of $1.50 per share of common stock (or, for investors who so choose, pre-funded warrants to purchase shares of its common stock) at a price to the public of $1.10 per share and accompanying Class C warrant (or $1.099 per pre-funded warrant and accompanying Class C warrant). X4 has also granted the underwriters a 30-day option to purchase up to an additional 8,865,000 shares of its common stock and/or Class C warrants to purchase up to an additional 4,432,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. X4's gross proceeds from this offering are expected to be approximately $65.0 million (or approximately $74.8 million if the underwriters exercise their option in full), before deducting underwriting discounts and estimated offering expenses and any proceeds from the exercise of the warrants to be issued in the offering. All of the securities in the offering are being sold by X4. The offering is expected to close on or about December 9, 2022, subject to customary closing conditions.

X4 Pharmaceuticals Prices $65.0 Million Public Offering

BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and accompanying warrants to purchase shares of its common stock (or pre-funded warrants). In addition, X4 expects to grant the underwriters a 30-day option to purchase additional shares of its common stock and/or warrants to purchase shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the securities in the offering will be sold by X4. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

X4 Pharmaceuticals Announces Proposed Public Offering

4WHIM trial meets primary endpoint and first key secondary endpoint, with mavorixafor achieving statistically significant and clinically relevant longer times above threshold levels for both absolute neutrophil (P

X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today announced that management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 15, 2022.

X4 Pharmaceuticals to Present at Stifel Healthcare Conference

BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the formation of its Clinical Scientific Advisory Board (“Clinical SAB”).

Scorpion Therapeutics Announces Formation of World-Class Clinical Scientific Advisory Board

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q3 2022 Results Conference Call November 3, 2022 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Paula Ragan - Chief Executive Officer Diego Cadavid - Chief Medical Officer Mark Baldry - Chief Commercial Officer Murray Stewart - Interim Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Eva Privitera - Cowen Mayank Mamtani - B. Riley Securities Trevor Allred - Oppenheimer Swayampakula Ramakanth - H.C.

X4 Pharmaceuticals, Inc. (XFOR) Q3 2022 Earnings Call Transcript

Following positive mavorixafor Phase 1b data release in multiple chronic neutropenic disorders, X4 continues to look forward to top-line results from its pivotal Phase 3 trial in WHIM syndrome in the fourth quarter of 2022

X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

A seasoned leader in the launch of rare and specialty pharmaceuticals, Mr. Baldry is expected to join X4 on November 3, 2022

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

BOSTON, Oct. 20, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the third quarter ended September 30, 2022 on November 3, 2022.

X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022

100% of study participants (n=25) achieved robust responses to oral mavorixafor

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor's Broad Potential in Chronic Neutropenia (CN)

X4 Pharmaceuticals is advancing Mavorixafor, a once-daily oral dose, first in class, small molecule antagonist of the CXCR4 receptor in WHIM syndrome and in chronic neutropenia disorders. On Sept 27, topline results will be presented from a Phase 1b trial testing Mavorixafor with or without G-CSF in patients with chronic neutropenia including severe congenital, idiopathic or cyclic.

X4 Pharmaceuticals: Upcoming Catalysts

Webcast to take place on September 27 at 8:00 a.m. ET, followed by live Q&A Webcast to take place on September 27 at 8:00 a.m. ET, followed by live Q&A

X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia

All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy

BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that management will present a corporate overview at the Canaccord Genuity 42nd Annual Growth Conference being held in Boston, MA, from August 8-11, 2022.

X4 Pharmaceuticals to Present at Canaccord Genuity's 42nd Annual Growth Conference

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors, IR Dr. Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Art Taveras - Chief Scientific Officer Diego Cadavid - Chief Medical Officer Mary DiBiase - Chief Operating Officer Conference Call Participants Stephen Willey - Stifel Eva Privitera - Cowen Mayank Mamtani - B. Riley Securities Arthur He - H.C.

X4 Pharmaceuticals, Inc.'s (XFOR) CEO Dr. Paula Ragan on Q2 2022 Results - Earnings Call Transcript

Highlights notable upcoming milestones including data from Phase 1b trial in chronic neutropenia, expected in late September, and results from global, pivotal Phase 3 trial in WHIM syndrome, expected in 4Q 2022

X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will report its financial results for the second quarter ended June 30, 2022, and provide an update on recent business highlights, on August 4, 2022.

X4 Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022

Company now focused on advancing lead clinical candidate mavorixafor in  chronic neutropenic disorders, including WHIM syndrome

X4 Pharmaceuticals Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

News for X4 Pharmaceuticals Inc Stock (XFOR)